Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Cost effectiveness calculations for the diagnosis and treatment of tuberculous meningitis

Abstract

This study illustrates how cost-effectiveness calculations provide help in decisions involving a choice between introduction of a new diagnostic procedure or a new therapy for a particular clinical problem. This type of problem is critical for areas where financial resources are limiting. Our analysis is centered on the value of diagnosis and treatment in tuberculous meningitis (Tbm) and, because of its importance to developing countries, our epidemiologic data were derived from India. When financial costs are ignored, the introduction of second line therapy (e.g., Rifampin) leads to more cures than does the introduction of even a perfect diagnostic test. However, diagnostic tests (e.g., the Bromide partition test or possibly radioassays) markedly improve case finding and to some extent increase cure rates. All affects vary markedly with the prevalence of tuberculous meningitis in the population under study. For example, net financial savings would occur were a perfect nuclear test available and conventional therapy used at a prevalence of Tbm of 30% whereas there would be a net loss if the prevalence rose to 80%.

This study underscores the need for detailed studies on the radiobromide partition test and for the development of new diagnostic tests, perhaps a radioimmunoassay of either the acid fast bacillus or of an antibody to it.

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. DaCosta, H., Borkar, A.: Technetium-99m permeation into cerebrospinal fluid. Clin. Nucl. Med. 4, 294–295 (1979)

  2. Mandal, B.K., Evans, D.I.K., Ironside, A.G., Pullan, B.R.: Radioactive bromide partition test in differential diagnosis of Tuberculous Meningitis. Br. Med. J. 4, 413–415 (1972)

  3. Maniar, B.: Prognosis of tuberculous meningitis in children. In: Tuberculosis of the nervous system, Kapila, C.C., Dastur, D.K., Singh, B., Tandon, P.N. (eds.), pp. 151–154. Indian Academy of Medical Sciences 1974

  4. Rangan, G., Virmani, V.: The bromide partition test in Tuberculous Meningitis: a re-evaluation. Indian J. Med. Res. 64, 131–137 (1976)

  5. Steiner, M., Steiner, P., Rao, M.: Primary drug-resistant tuberculosis in children, 1961 to 1971. Am. Rev. Resp. Dis. 108, 321–327 (1973)

  6. Udani, P.M.: Tuberculosis in children in practice. Doctor to Doctor I, 127–150 (1976)

  7. Udani, P.M., Bhat, U.S., Bhave, S.K.: Problem of tuberculosis in children in India. Epidemiology, morbidity, mortality and control programme. Indian Pediat. 13, 881–890 (1976)

  8. Vejjajiva, A., Poshayachinda, V., Poshayachinda, M.: Radioactive bromide test in Tuberculous Meningitis. Neurology (India) 20, 151 (1972)

  9. Visudhiphan, P., Chiemchanya, S.: Evaluation of rifampicin in the treatment of tuberculous meningitis in children. J. Pediat. 87, 983–986 (1975)

Download references

Author information

Additional information

This work was supported in part by a contract from the International Atomic Energy Agency. Dr. McNeil is a recipient of Research Career Development Award 5-K04-GM00194 from the National Institute of General Medical Sciences

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McNeil, B.J., Thompson, M. & Adelstein, S.J. Cost effectiveness calculations for the diagnosis and treatment of tuberculous meningitis. Eur J Nucl Med 5, 271–276 (1980). https://doi.org/10.1007/BF00271911

Download citation

Keywords

  • Bacillus
  • Meningitis
  • Diagnostic Test
  • Financial Resource
  • Conventional Therapy